参考文献/References:
［1］ SHI H M,WU C J,LIN S L.Physiology and pathophysiology of renal erythropoietin-producing cells［J］.J Formos Med Assoc,2018,117(11):955-963.
［2］ UNGER E F,THOMPSON A M,BLANK M J,et al.Erythropoiesis-stimulating agents-time for a reevaluation［J］.N Engl J Med,2010,362(3):189-192.
［3］ WEISS G,GANZ T,GOODNOUGH L T.Anemia of inflammation［J］.Blood,2019,133(1):40-50.
［4］ BEGUM S,LATUNDE-DADA G O.Anemia of inflammation with an emphasis on chronic kidney disease ［J］.Nutrients,2019,11(10):2424.
［5］ FINKELSTEIN F O,FINKELSTEIN S H.The impact of anemia treatment on health-related quality of life in patients with chronic kidney disease in the contemporary era［J］.Adv Chronic Kidney Dis,2019,26(4):250-252.
［6］ VECCHIO L D,MINUTOLO R.ESA,iron therapy and new drugs:are there new perspectives in the treatment of anaemia［J］.J Clin Med,2021,10(4):839.
［7］ LUCIA D V，ROBERT E,FERRO C J,et al.Intravenous iron therapy and the cardiovascular system:risks and benefits［J］.Clin Kidney J,2020,4（14）:1067-1076.
［8］ SCHODEL J,RATCLIFFE P J.Mechanisms of hypoxia signaling:new implications for nephrology［J］.Nat Rev Nephrol,2019,15(10):641-659.
［9］ HAASE V H.Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic［J］.Kidney Int Suppl,2021,11(1)：8-25.
［10］ KILE M，SUDCHADA P.Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors:a narrative review［J］.Int Urol Nephrol,2021,53(2):283-290.
［11］ WIESENER M S，JURGENSEN J S，ROSENBERGER C,et al.Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs［J］.FASEB J,2003,17(2):271-273.
［12］ WANG K,WU J,XU J,et al.Correction of anemia in chronic kidney disease with Angelica sinensis polysaccharide via restoring EPO production and improving iron availability［J］.Front Pharmacol,2018,9:803.
［13］ YAP D Y H,MCMAHON L P,HAO C M,et al.Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors［J］.Nephrology (Carlton),2021,26(2):105-118.
［14］ CHAN M C,HOLT-MARTYN J P,SCHOFIELD C J,et al.Pharmacological targeting of the HIF hydroxylases-a new field in medicine development［J］.Mol Aspects Med,2016,47/48:54-75.
［15］ SANGHANI N S,HAASE V H.Hypoxia-inducible factor activators in renal anemia:current clinical experience［J］.Adv Chronic Kidney Dis,2019,26(4):253-266.
［16］ SCHWARTZ A J,DAS N K,RAMAKRISHNAN S K,et al.Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload［J］.J Clin Invest,2019,129(1):336-348.
［17］ MASTROGIANNAKI M,MATAK P,KEITH B，et al.HIF-2α,but not HIF-1alpha,promotes iron absorption in mice［J］.J Clin Invest,2009,119(5):1159-1166.
［18］ TAYLOR M,QU A,ANDERSON E R,et al.Hypoxia-inducible fctor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice［J］.Gastroenterology,2011,140(7):2044-2055.
［19］ XU M M,WANG J,XIE J X.Regulation of iron metabolism by hypoxia-inducible factors［J］.Acta physiologica Sinica,2017,69(5):598-610.
［20］ TACCHINI L,BIANCHI L,BERNELLI-ZAZZERA A,et al.Transferrin receptor induction by hypoxia.HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation［J］.J Biol Chem,1999,274(34):24142-24146.
［21］ TACCHINI L，POLI F D，BERNELLI-ZAZZERA A，et al.Transferrin receptor gene expression and transferrin-bound iron uptake are increased during postischemic rat liver reperfusion［J］.Hepatology,2002,36(1):103-111.
［22］ BIANCHI L,TACCHINI L,CAIRO G.HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation［J］.Nucleic Acids Res,1999,27(21):4223-4227.
［23］ LUO Q Q,WANG D,YU M Y,et al.Effect of hypoxia on the expression of iron regulatory proteins 1 and the mechanisms involved［J］.IUBMB Life,2011,63(2):120-128.
［24］ AGARWAL A K.Iron metabolism and management:focus on chronic kidney disease［J］.Kidney Int Suppl,2021,11(1):46-58.
［25］ SHINOZAKI Y,FUKUI K,KOBAYASHI H,et al.JTZ-951 (enarodustat),a hypoxia-inducible factor prolyl hydroxylase inhibitor,improves iron utilization and anemia of inflammation:comparative study against recombinant erythropoietin in rat［J］.Eur J Pharmacol,2021,898:173990.
［26］ BATCHELOR E K,KAPITSINOU P,PERGOLA P E,et al.Iron deficiency in chronic kidney disease:updates on pathophysiology,diagnosis,and treatment［J］.J Am Soc Nephrol,2020,31(3):456-468.
［27］ SROLE D N,GANZ T.Erythroferrone structure,function,and physiology:iron homeostasis and beyond［J］.J Cell Physiol,2021,236(7):4888-4901.
［28］ AREZES J,FOY N,MCHUGH K,et al.Erythroferrone inhibits the induction of hepcidin by BMP6［J］.Blood,2018,132(14):1473-1477.
［29］ GROENENDAAL-VAN DE MEENT D,DEN ADEL M,VAN DIJK J,et al.Effect of multiple doses of omeprazole on the pharmacokinetics,safety,and tolerability of roxadustat in healthy subjects［J］.Eur J Drug Metab Pharmacokinet,2018,43(6):685-692.
［30］ SHIBATA T,NOMURA Y,TAKADA A,et al.Evaluation of food and spherical carbon adsorbent effects on the pharmacokinetics of roxadustat in healthy nonelderly adult male japanese subjects［J］.Clin Pharmacol Drug Dev,2019,8(3):304-313.
［31］ SHIBATA T,NOMURA Y,TAKADA A,et al.Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects［J］.J Clin Pharm Ther,2018,43(5):633-639.
［32］ CHEN N,QIAN J,CHEN J,et al.Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China［J］.Nephrol Dial Transplant,2017,32(8):1373-1386.
［33］ PROVENZANO R,BESARAB A,WRIGHT S,et al.Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis:a phase 2,randomized,6- to 19-week,open-label,active-comparator,dose-Ranging,safety and exploratory efficacy study［J］.Am J Kidney Dis,2016,67(6):912-924.
［34］ BESARAB A,CHERNYAVSKAYA E,MOTYLEV I,et al.Roxadustat (FG-4592):correction of anemia in incident dialysis patients［J］.J Am Soc Nephrol,2016,27(4):1225-1233.
［35］ CHEN N,HAO C,PENG X,et al.Roxadustat for anemia in patients with kidney disease not receiving dialysis［J］.N Engl J Med,2019,381(11):1001-1010.
［36］ CHEN N,HAO C,LIU B C,et al.Roxadustat treatment for anemia in patients undergoing long-term dialysis［J］.N Engl J Med,2019,381(11):1011-1022.
［37］ AKIZAWA T,IWASAKI M,YAMAGUCHI Y,et al.Phase 3,randomized,double-blind,active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in japan［J］.J Am Soc Nephrol,2020,31(7):1628-1639.
［38］ AKIZAWA T,YAMAGUCHI Y,OTSUKA T,et al.A phase 3,multicenter,randomized,two-arm,open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in japanese erythropoiesis-stimulating agent-nave chronic kidney disease patients not on dialysis［J］.Nephron,2020,144(8):372-382.
［39］ COYNE D W,ROGER S D,SHIN S K,et al.Roxadustat for CKD-related anemia in non-dialysis patients［J］.Kidney Int Rep,2020,6(3):624-635.
［40］ PROVENZANO R,SHUTOV E,EREMEEVA L,et al.Roxadustat for anemia in patients with end-stage renal disease incident to dialysis［J］.Nephrol Dial Transplant,2021,online ahead of print.DOI:10.1093/ndt/gfab051.
［41］ SHUTOV E,SULOWICZ W,ESPOSITO C,et al.Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis:a phase 3,randomized,double-blind,placebo-controlled study (ALPS)［J］.Nephrol Dial Transplant,2021,online ahead of print.DOI:10.1093/ndt/gfab057.
［42］ FISHBANE S,El-SHAHAWY M A,PECOITS-FILHO R,et al.Roxadustat for treating anemia in patients with CKD not on dialysis:results from a randomized phase 3 study［J］.J Am Soc Nephrol,2021,32(3):737-755.
［43］ QIE S,JIAO N,DUAN K,et al.The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease:a meta-analysis and systematic review［J］.Int Urol Nephrol,2021,10:1007-1020.